Photo taken from Mahadi Baig/LinkedIn
Aug 17, 2024, 08:15
Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s subcutaneous treatment for patients with EGFR-mutated NSCLC
Mahadi Baig, Johnson and Johnson, shared a post on LinkedIn:
“I’m pleased to announce that today, the U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine’s application for a subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
This treatment, with its potential to transform the treatment experience for patients, clearly demonstrates our team’s unwavering commitment to a ‘patient-centric‘ approach to developing better therapies.
I am incredibly proud of this team as we continue to put patients at the forefront of everything we do.
Learn more about the submission.”
Source: Mahadi Baig/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27